ATE253633T1 - Cystic fibrosis gen - Google Patents
Cystic fibrosis genInfo
- Publication number
- ATE253633T1 ATE253633T1 AT90912428T AT90912428T ATE253633T1 AT E253633 T1 ATE253633 T1 AT E253633T1 AT 90912428 T AT90912428 T AT 90912428T AT 90912428 T AT90912428 T AT 90912428T AT E253633 T1 ATE253633 T1 AT E253633T1
- Authority
- AT
- Austria
- Prior art keywords
- sequence
- amino acid
- dna
- dna sequences
- acid residue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4712—Cystic fibrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39689489A | 1989-08-22 | 1989-08-22 | |
US39994589A | 1989-08-24 | 1989-08-24 | |
US40160989A | 1989-08-31 | 1989-08-31 | |
PCT/CA1990/000267 WO1991002796A1 (en) | 1989-08-22 | 1990-08-20 | Cystic fibrosis gene |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE253633T1 true ATE253633T1 (de) | 2003-11-15 |
Family
ID=27410233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90912428T ATE253633T1 (de) | 1989-08-22 | 1990-08-20 | Cystic fibrosis gen |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0489058B1 (de) |
JP (3) | JPH05500306A (de) |
AT (1) | ATE253633T1 (de) |
CA (1) | CA2066204C (de) |
DE (1) | DE69034115T2 (de) |
DK (1) | DK0489058T3 (de) |
ES (1) | ES2210224T3 (de) |
IE (2) | IE20040698A1 (de) |
WO (1) | WO1991002796A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543399A (en) * | 1989-08-22 | 1996-08-06 | Hsc Research & Development Limited Partnership | Cystic fibrosis transmembrane conductance regulator (CFTR) protein |
US6063913A (en) * | 1989-08-22 | 2000-05-16 | Hsc Research And Development Limited Partnership | Stable heterologous propagation CFTR protein variant cDNA |
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US6984487B1 (en) | 1989-08-22 | 2006-01-10 | Hsc Research Development Corporation | Cystic fibrosis gene |
EP0667900B1 (de) * | 1990-01-12 | 2001-05-23 | HSC Research Development Corporation | Introns und exons des gens für cystische fibrose sowie mutationen an mehreren stellen des gens |
US5981714A (en) * | 1990-03-05 | 1999-11-09 | Genzyme Corporation | Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor |
US20020164782A1 (en) | 1999-02-10 | 2002-11-07 | Gregory Richard J. | Adenovirus vectors for gene therapy |
US5939536A (en) * | 1990-03-05 | 1999-08-17 | Genzyme Corporation | Methods for purifying cystic fibrosis transmembrane conductance regulation |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US7118911B1 (en) | 1990-03-05 | 2006-10-10 | Genzyme Corporation | DNA molecules stabilized for propagation in bacterial cells that encode cystic fibrosis transmembrane conductance regulator |
CA2037478A1 (en) * | 1990-03-05 | 1991-09-06 | Richard Gregory | Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator |
US5674898A (en) * | 1990-03-05 | 1997-10-07 | Genzyme Corporation | Methods and therapeutic compositions for treating cystic fibrosis |
AU2143992A (en) * | 1991-08-16 | 1993-03-16 | Vical, Inc. | Composition and method for treating cystic fibrosis |
US6013638A (en) * | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
WO1993012240A1 (en) * | 1991-12-17 | 1993-06-24 | The Regents Of The University Of California | Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr) |
US6627615B1 (en) | 1991-12-17 | 2003-09-30 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
IL105914A0 (en) * | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
GB9217885D0 (en) * | 1992-08-21 | 1992-10-07 | Medical Res Council | Mutant mice |
FR2700011B1 (fr) * | 1992-12-24 | 1995-02-24 | Inst Nat Sante Rech Med | Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP. |
US5582825A (en) * | 1993-02-24 | 1996-12-10 | Gunze Limited | Therapeutic medicine for cystic fibrosis |
WO1995007453A1 (en) * | 1993-09-08 | 1995-03-16 | Genzyme Corporation | A method for purifying a membrane-associated protein |
US5688677A (en) * | 1993-10-13 | 1997-11-18 | Genzyme Corporation | Deoxyribonucleic acids containing inactivated hormone responsive elements |
US5639661A (en) * | 1994-03-23 | 1997-06-17 | The University Of Iowa Research Foundation | Genes and proteins for treating cystic fibrosis |
US6344445B1 (en) | 1995-10-19 | 2002-02-05 | Cantab Pharmaceutical Research Limited | Herpes virus vectors and their uses |
US6245735B1 (en) | 1996-07-29 | 2001-06-12 | The Brigham And Women's Hospital, Inc. | Methods and products for treating pseudomonas infection |
US5858671A (en) * | 1996-11-01 | 1999-01-12 | The University Of Iowa Research Foundation | Iterative and regenerative DNA sequencing method |
US6258533B1 (en) | 1996-11-01 | 2001-07-10 | The University Of Iowa Research Foundation | Iterative and regenerative DNA sequencing method |
CA2311640A1 (en) * | 1997-12-03 | 1999-06-10 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
EP1191101B1 (de) * | 1997-12-11 | 2004-06-09 | Genentech, Inc. | PRO241 Polypeptide und dafür kodierende Nukleinsäuren |
AU2001265728A1 (en) | 2000-06-08 | 2001-12-17 | Lawson Research Institute | Diagnosis and classification of disease and disability using low frequency magnetic field designed pulses (cnps) |
US7119172B2 (en) | 2001-05-21 | 2006-10-10 | The Brigham And Women's Hospital, Inc. | P. aeruginosa mucoid exopolysaccharide specific binding peptides |
WO2002094854A2 (en) | 2001-05-21 | 2002-11-28 | The Brigham And Women's Hospital, Inc. | P.aeruginosa mucoid exopolysaccharide specific binding peptides |
EP1655608A1 (de) * | 2004-11-04 | 2006-05-10 | Inserm | CFTR als Komponente vom Autophagie-Signalweg, deren Verwendung in autophagischen Krankheiten, und Bestimmung von Mukoviszidose als autophagische Krankheit |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
WO2011119531A1 (en) | 2010-03-22 | 2011-09-29 | Esoterix Genetic Laboratories, Llc | Mutations associated with cystic fibrosis |
WO2013181446A2 (en) | 2012-05-30 | 2013-12-05 | University Of Medicine And Dentistry Of New Jersey | Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid |
SG11202107969SA (en) * | 2019-02-08 | 2021-08-30 | Krystal Biotech Inc | Compositions and methods for delivering cftr polypeptides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8709652D0 (en) * | 1987-04-23 | 1987-05-28 | Williamson R | Diagnosis of cystic fibrosis |
CA2037478A1 (en) * | 1990-03-05 | 1991-09-06 | Richard Gregory | Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator |
-
1990
- 1990-08-20 CA CA002066204A patent/CA2066204C/en not_active Expired - Lifetime
- 1990-08-20 AT AT90912428T patent/ATE253633T1/de not_active IP Right Cessation
- 1990-08-20 ES ES90912428T patent/ES2210224T3/es not_active Expired - Lifetime
- 1990-08-20 DE DE69034115T patent/DE69034115T2/de not_active Expired - Lifetime
- 1990-08-20 WO PCT/CA1990/000267 patent/WO1991002796A1/en active IP Right Grant
- 1990-08-20 DK DK90912428T patent/DK0489058T3/da active
- 1990-08-20 EP EP90912428A patent/EP0489058B1/de not_active Expired - Lifetime
- 1990-08-20 EP EP03078489A patent/EP1418183A1/de not_active Withdrawn
- 1990-08-20 JP JP2511424A patent/JPH05500306A/ja active Pending
- 1990-08-21 IE IE20040698A patent/IE20040698A1/en not_active Application Discontinuation
- 1990-08-21 IE IE302490A patent/IE903024A1/en not_active IP Right Cessation
-
2001
- 2001-11-29 JP JP2001402257A patent/JP2002355088A/ja not_active Withdrawn
-
2004
- 2004-02-05 JP JP2004029998A patent/JP2004208694A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0489058A1 (de) | 1992-06-10 |
AU6161690A (en) | 1991-04-03 |
EP1418183A1 (de) | 2004-05-12 |
JP2002355088A (ja) | 2002-12-10 |
DE69034115T2 (de) | 2004-07-15 |
JP2004208694A (ja) | 2004-07-29 |
CA2066204A1 (en) | 1991-02-23 |
WO1991002796A1 (en) | 1991-03-07 |
CA2066204C (en) | 2009-03-31 |
JPH05500306A (ja) | 1993-01-28 |
DK0489058T3 (da) | 2004-03-22 |
EP0489058B1 (de) | 2003-11-05 |
IE903024A1 (en) | 1991-02-27 |
IE20040698A1 (en) | 2004-12-01 |
ES2210224T3 (es) | 2004-07-01 |
AU647408B2 (en) | 1994-03-24 |
DE69034115D1 (en) | 2003-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE253633T1 (de) | Cystic fibrosis gen | |
DE3854952D1 (de) | Mykobakterielle rekombinanten und peptide | |
ES2009238A6 (es) | Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas. | |
NZ502391A (en) | Mammalian cytokine: interleukin-B30 and related reagents | |
AU659330B2 (en) | RNA catalyst for cleaving specific RNA sequences | |
ATE310090T1 (de) | Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren | |
HK1013847A1 (en) | Gdf-1 and uog-1 proteins | |
DE69731834D1 (de) | Agouti verwandtes gen | |
FI962247A (fi) | Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät | |
NO179412C (no) | Hybrid DNA-molekyl som koder for fibronektinbindende protein, mikroorganismer inneholdende slike DNA-molekyler samt fremgangsmåte ved fremstilling av slikt protein | |
EP2014770A3 (de) | WNT-1-induziertes sekretiertes Polypeptid WISP-2 | |
AU8127494A (en) | Chimeric proteins comprising borrelia polypeptides: uses therefor | |
CA2192940A1 (en) | Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections | |
DE69739524D1 (de) | Dp-75 kodierende dna und verfahren zu ihrer verwendung | |
WO1993017031A3 (en) | Nucleic acids encoding dystrophin-associated proteins | |
EP0835933A3 (de) | Ein Protein G-gekoppelter Rezeptor, HLTEX11 | |
DE3587205T2 (de) | Verfahren zur herstellung eines proteins und dafuer zu verwendender vektor, rekombinante dns und transformierte zelle. | |
DE3572843D1 (en) | Site-specific proteolysis by renin | |
ATE122055T1 (de) | Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung. | |
KR900003369A (ko) | 모티린형 폴리펩티드의 제조방법 및 그것의 발현 | |
DK551786A (da) | Rekombinant-dna-sekvens, der koder for aminosyresekvenser i et toksin, expressionssystem omfattende samme og vaertsceller transformeret hermed | |
WO1999049045A3 (de) | Rekombinantes hauptallergen des pollens von artemisia vulgaris (beifuss) | |
ATE547427T1 (de) | Verfahren zur rekombinanten herstellung von ribonukleoproteinen | |
WO1999019491A3 (en) | Human dnax interleukin-40 (dil-40) | |
ATE409225T1 (de) | Durch wnt-1 induzierbare gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0489058 Country of ref document: EP |
|
EELA | Cancelled due to lapse of time |